Very promising results were obtained when the GE11-conjugated doxorubicin filled liposomes (GE11-PS-Dox) were used to treat ovarian cancer xenograft bearing mice, indicating GE11-guided drug targeting as an alternative for treatment of EGFR overexpressing ovarian cancers [199]. The gene discussed is EGFR; the disease is ovarian cancer.